Receptors, Estrogen

"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.

Descriptor ID	D011960
MeSH Number(s)	D12.776.826.750.350 D12.776.930.778.350
Concept/Terms	Receptors, Estrogen Receptors, Estrogen Estrogen Receptors Receptors, Estrogen, Type II Receptors, Estrogen, Type II Estrogen Receptor Type II Estrogen Receptors Type II Estrogen Nuclear Receptor Estrogen Nuclear Receptor Nuclear Receptor, Estrogen Receptor, Estrogen Nuclear Receptors, Estrogen, Type I Receptors, Estrogen, Type I Estrogen Receptor Type I Estrogen Receptors Type I

Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Receptors, Cytoplasmic and Nuclear [D12.776.826]
Receptors, Steroid [D12.776.826.750]
Receptors, Estrogen [D12.776.826.750.350]
Transcription Factors [D12.776.930]
Receptors, Steroid [D12.776.930.778]
Receptors, Estrogen [D12.776.930.778.350]

Below are MeSH descriptors whose meaning is related to "Receptors, Estrogen".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.

Bar chart showing 149 publications over 28 distinct years, with a maximum of 14 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1997	1	0	1
1998	1	0	1
1999	2	0	2
2000	1	2	3
2001	3	2	5
2002	5	3	8
2003	5	4	9
2004	4	4	8
2005	2	5	7
2006	1	5	6
2007	3	8	11
2008	4	6	10
2009	3	6	9
2010	6	8	14
2011	3	5	8
2012	3	3	6
2013	1	2	3
2014	2	3	5
2015	1	5	6
2016	4	1	5
2017	0	1	1
2018	0	5	5
2019	1	2	3
2020	2	1	3
2021	0	3	3
2022	0	5	5
2023	0	1	1

Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.

Alam R, Reva A, Edwards DG, Lege BM, Munoz-Arcos LS, Reduzzi C, Singh S, Hao X, Wu YH, Tian Z, Natalee LM, Damle G, Demircioglu D, Wang Y, Wu L, Molteni E, Hasson D, Lim B, Gugala Z, Chipuk JE, Lang JE, Sparano JA, Cheng C, Cristofanilli M, Xiao H, Zhang XH, Bado IL. Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. Cancer Discov. 2025 Apr 02; 15(4):818-837.

View in: PubMed
Kamaraju S, Fowler AM, Tarima S, Chaudhary LN, Burkard ME, Giever T, Cheng YC, Parkes A, Lange CA, Pipp-Dahm M, Hegeman R, Siddiqui N, Stella A, Rajguru S, Twaroski K, Zurbriggen L, Jorns JM, Rui H, Keigley QJ, Perlman SB, Salem K, Bradshaw TJ, Sahmoud T, Wisinski K. A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer. Clin Breast Cancer. 2025 Apr; 25(3):251-260.

View in: PubMed
Ping J, Jia G, Cai Q, Guo X, Tao R, Ambrosone C, Huo D, Ambs S, Barnard ME, Chen Y, Garcia-Closas M, Gu J, Hu JJ, John EM, Li CI, Nathanson K, Nemesure B, Olopade OI, Pal T, Press MF, Sanderson M, Sandler DP, Yoshimatsu T, Adejumo PO, Ahearn T, Brewster AM, Hennis AJM, Makumbi T, Ndom P, O'Brien KM, Olshan AF, Oluwasanu MM, Reid S, Yao S, Butler EN, Huang M, Ntekim A, Li B, Troester MA, Palmer JR, Haiman CA, Long J, Zheng W. Using genome and transcriptome data from African-ancestry female participants to identify putative breast cancer susceptibility genes. Nat Commun. 2024 May 02; 15(1):3718.

View in: PubMed
Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023 Mar; 19(8):559-573.

View in: PubMed
Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga R, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel E, Pirrie S, Schnabel CA, Rea D, Bartlett JMS. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Breast Cancer Res. 2022 12 16; 24(1):90.

View in: PubMed
Lee J, Kim H, Bae SJ, Ji JH, Lee JW, Son BH, Ahn SH, Jeong J, Lee SB, Ahn SG. Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor-Positive, ERBB2-Negative Breast Cancer. JAMA Netw Open. 2022 11 01; 5(11):e2243935.

View in: PubMed
Bedard PL, Li S, Wisinski KB, Yang ES, Limaye SA, Mitchell EP, Zwiebel JA, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. JCO Precis Oncol. 2022 07; 6:e2200165.

View in: PubMed
Cobain EF, Hayes DF. Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 2022 11 10; 40(32):3673-3676.

View in: PubMed
Acs B, Leung SCY, Kidwell KM, Arun I, Augulis R, Badve SS, Bai Y, Bane AL, Bartlett JMS, Bayani J, Bigras G, Blank A, Buikema H, Chang MC, Dietz RL, Dodson A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hartman J, Kos Z, L?nkholm AV, Laurinavicius A, Levenson RM, Mahboubi-Ardakani R, Mastropasqua MG, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Quintayo MA, Rau TT, Reinhard S, Robertson S, Salgado R, Sugie T, van der Vegt B, Viale G, Zabaglo LA, Hayes DF, Dowsett M, Nielsen TO, Rimm DL. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Mod Pathol. 2022 10; 35(10):1362-1369.

View in: PubMed
Chae SY, Park SH, Lee HS, Ahn JH, Kim SB, Jung KH, Kim JE, Ahn SH, Son BH, Lee JW, Ko BS, Kim HJ, Gong G, Oh JS, Park SY, Moon DH. Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. Sci Rep. 2022 05 12; 12(1):7858.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement